Registry and Biobank of Patients With a History of Cancer Therapy to Study Ocular Complications

What this Trial Is About

Researchers are studying patients who have undergone cancer therapy to better understand eye problems that may arise from such treatments, including graft versus host disease (GVHD) and corneal toxicity. The study aims to collect detailed information and biological samples to investigate the immune and cellular changes related to these ocular complications. Patients with a history of cancer treatment and control participants without such history will be compared to identify factors predicting eye issues after cancer therapy. Participants will receive a standard eye exam as part of their routine care. Those in the cancer therapy group will also have biological samples collected, such as tears, cells from the eye surface, and blood, which will be stored and analyzed to study disease mechanisms. The study involves two groups: cancer therapy patients and controls without cancer therapy history. During the study, participants will provide their medical and eye history, undergo clinical evaluations, and have biological specimens collected. The primary outcome measured is the severity of chronic ocular GVHD, assessed at the time of the eye exam, typically between 3 months and up to 10 years after transplant, with an average around 3 years post-transplant. Data collection will continue until April 2031, with all procedures performed during routine ophthalmology visits.

Ocular Complications From Cancer Therapy - Patient Registry and Biobank